Resunab

Resunab, a promising future treatment for lupus.

Resunab, a promising future treatment for lupus.

Patent holder Corbus Pharmaceuticals is putting the drug, branded Resunab, through its clinical paces.

Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is non psychoactive.

In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic profile. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis.